Fifty Years with Interferons

In 1981 Sidney Pestka and colleagues at Roche purified recombinant human leukocyte interferon from bacteria setting the stage for its structure elucidation. Credit: COURTESY OF SIDNEY PESTKA / PBL BIOMEDICAL LABORATORIES" />In 1981 Sidney Pestka and colleagues at Roche purified recombinant human leukocyte interferon from bacteria setting the stage for its structure elucidation. Credit: COURTESY OF SIDNEY PESTKA / PBL BIOMEDICAL LABORATORIES In 1957, Alick Isaacs and Jean Lindenmann, b

Written byAndrea Gawrylewski
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In 1957, Alick Isaacs and Jean Lindenmann, both at the National Institute for Medical Research in London, set out to understand why inactivated influenza virus could induce interference in cells and tissues, preventing infection by "live" virus.

That the inactivated viruses physically blocked infection seemed unlikely. So, the two incubated chorio-allatoic membranes from chicken eggs with heat-inactivated influenza. They then washed the membranes and tried to infect them with normal virus. An interfering agent produced in response to the inactive virus seemed to be protecting both incubated membranes and fresh membranes placed in the fluids from incubated membranes. "To distinguish it from the heated influenza virus," the authors wrote, "we have called the newly released interfering agent, 'interferon.'"1

Interferon was thought to apply strictly to viruses, but subsequent research showed that interferon could inhibit intracellular bacteria and tumorigenesis. Because interferon is secreted in minute amounts, it took nearly 20 years ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies